Clinical Development of Antiepileptic Drugs in Adults

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 62-69

  Schmidt, Bernd ^a  

^a Neurology and Psychiatry Clinic   (Germany)

Author keywords

adjunctive trials; AED development; Antiepileptic drugs (AED); clinical trials; monotherapy

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG APPROVAL; DRUG INFORMATION; DRUG MONITORING; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; GRAND MAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LENNOX GASTAUT SYNDROME; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MYOCLONUS EPILEPSY; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; SEIZURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTICONVULSANTS; CLINICAL TRIALS; DRUG EVALUATION; EPILEPSY; HUMANS;

EID: 33846402434     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.11.013     Document Type: Article

References (26)

1. Katz R. FDA update. Epilepsy Res 68 (2006) 85-94
2. White S. Preclinical development of antiepileptic drugs: past, present and future directions. Epilepsia 44 suppl 7 (2003) 2-8
3. Bickerstaffe R., Brock P., Husson J.-M., et al. Ethics and pharmaceutical medicine. Int J Clin Pract 60 (2006) 242-252
4. Schmidt B. Gabapentin. In: Levy R., Mattson R., Meldrum B., Penry I., and Dreifuss F.E. (Eds). Antiepileptic drugs. 3rd ed. (1989), Raven Press, New York chap 68
5. Wolf P, Schmidt B. Early phase II testing of ralitoline. Excerpta Medica 1988:ISBN 444-01365-2:45-56.
6. Messenheimer J., Ramsay R.E., Willmore L.J., et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35 (1994) 113-121
7. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 335 (1990) 1114-1117
8. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 43 (1993) 2292-2298
9. Sachdeo R.C., Glauser T.A., Ritter F., Reife R., Lim P., Pledger G., and Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52 (1999) 1882-1887
10. Littman B.H., and Williams S.A. The ultimate model organism: progress in experimental medicine. Nat Rev Drug Discov 4 (2005) 631-638
11. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1 (2004) 189-195
12. Schmidt B. Proof of principle studies. Epilepsy Res 68 (2006) 48-52
13. Schmidt B. How to avoid misinterpreting results of clinical trials. Epilepsia 46 suppl 6 (2005) 18
14. Benedetti M.S. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14 (2000) 301-319
15. Burneo J.G., Montori V.M., and Faught E. Placebo effect in antiepileptic drug trials. Epilepsy Behav 4 (2003) 371
16. Pledger G.W., and Sahlroot J.T. Alternative analyses for antiepileptic drug trials. Epilepsy Res Suppl 10 (1993) 167-174
17. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41 (2000) 1597-1607
18. Schmidt B. Randomized monotherapy trials of new anti-epileptic drugs. Can "evidence-based medicine" be misleading?. Epilepsia 43 suppl 8 (2002) 21-22
19. Baker G.A., Currie N.J., Light M.J., et al. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy - a Canadian study. Seizure 11 (2002) 6-15
20. Ben-Menachem E., Edrich P., Van Vleyman B., Sander J.W.A.S., and Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53 (2003) 57-64
21. Wong I.C.K., and Lhatoo S.D. Adverse reactions to new anticonvulsant drugs. Drug Saf 23 (2000) 35-56
22. French J.A., and Schachter S. A Workshop on AED monotherapy. Epilepsia 43 suppl 10 (2002) 3-27
23. Beydoun A., Fischer J., Labar D.R., et al., The US Gabapentin Study Group 82/83. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology 49 (1997) 746-752
24. Bergey G.K., Morris H.H., Rosenfeld W., et al., The US Gabapentin Study Group 88/89. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 49 (1997) 739-745
25. Schachter S.C., Vazquez B., Fisher R.S., et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 52 (1999) 732-737
26. Arroyo S., Dodson W.E., Privitera M.D., et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112 (2005) 214-222